Clinical trial readout dates for Indivior Pharmaceuticals Inc., compiled from
ClinicalTrials.gov, alongside the SEC filings where results are announced.
Market cap$5.1B
Cash & investments$305Mas of Sep 30, 2026
Recent 8-K filings3latest 2026-11-03
In progress, no date published
Phase 2INDV-6001
Opioid Use Disorder (OUD)
date not published
Ongoing
Cash position
Indivior Pharmaceuticals Inc. reported $305M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). It reported net income of $137M for that quarter.